Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eagle Capital Growth Fund (GRF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

, and , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
ICU Medical Broadens its Non-PVC/Non-DEHP IV Solutions Portfolio by Entering Long-Term U.S. Distribution Agreement with Grifols for Certain Core IV Solution Products

SAN CLEMENTE, Calif., /PRNewswire/ --  (NASDAQ: ICUI) today announced that it has entered into a long-term agreement with to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium...

ICUI : 183.45 (-1.14%)
GRF : 6.76 (-0.59%)
Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

and , /PRNewswire/ -- A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor...

MSFT : 203.19 (+1.30%)
GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Grifols Procleix Panther System with Automation Ready Technology (ART) receives FDA Approval

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Grifols launches new 3-mL (900-IU) vial for high-potency HyperRAB® (rabies immune globulin [human])

Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of a new 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]), a...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
People Who Have Recovered from COVID-19 Can Now Donate their Convalescent Plasma in select Grifols U.S. Plasma Donor Centers

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines,...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Grifols 2019 Annual Report on Form 20-F Filed With the SEC on April 6, 2020

Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2019 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Grifols 2019 Annual Report on Form 20-F Filed With the SEC on April 6, 2020

BARCELONA, Spain , April 6, 2020 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2019 Annual Report on Form 20-F with the United States...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
GIFLF : 27.2524 (-4.04%)
GIFOF : 16.4380 (+1.36%)
GIKLY : 14.0000 (-2.78%)
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19

Grifols today announces that it has entered into a formal collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Grifols PharmacyKeeper ranked No. 1 in KLAS rating, extends category leadership

Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced...

WORK : 26.59 (+0.83%)
GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Green Rise Capital Corporation Announces Stock Ticker Symbol Change to "GRF" and the Corporate Brand Name to Green Rise Foods

Toronto, Ontario--(Newsfile Corp. - January 14, 2020) - ("Green Rise" or the "Company")  announced today that it has registered "Green Rise Foods" as a business name and will begin to conduct business...

GRF : 6.76 (-0.59%)
GRF.VN : 0.450 (+2.27%)
GRCC.VN : 0.175 (unch)
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment

Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Grifols presents its latest Alzheimer's clinical trial data

Neuroimaging shows AMBAR clinical trial's positive effects in patients with mild-to-moderate Alzheimer's disease

GRFS : 16.71 (+2.83%)
GRF : 6.76 (-0.59%)
Grifols presents its latest Alzheimer's clinical trial data

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging results of its AMBAR (Alzheimer Management by Albumin...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Grifols Streamlines Hospital Pharmacy Operations With New KIRO Fill® Technology and PharmacyKeeper Enhancements

Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced...

GRF.VN : 0.450 (+2.27%)
GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Grifols Streamlines Hospital Pharmacy Operations With New KIRO Fill® Technology and PharmacyKeeper Enhancements

BARCELONA, Spain , Dec. 5, 2019 /PRNewswire/ --   Grifols   (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and...

GRFS : 16.71 (+2.83%)
GIKLY : 14.0000 (-2.78%)
GIFOF : 16.4380 (+1.36%)
GIFLF : 27.2524 (-4.04%)
GRF : 6.76 (-0.59%)
Grifols to present latest Alzheimer's clinical trial results

Grifols , a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer Management by Albumin Replacement)...

GRFS : 16.71 (+2.83%)
GRF : 6.76 (-0.59%)
Grifols to present latest Alzheimer's clinical trial results

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)
Grifols introduces AlphaID(TM), a free cheek swab to screen for Alpha-1, the most common genetic form of COPD

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, has now introduced AlphaID(TM), a...

GRF : 6.76 (-0.59%)
GRFS : 16.71 (+2.83%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar